IsoPlexis Exit

When patients need treatment for certain diseases, such as cancer, it’s not always immediately apparent which therapies they’ll respond to best. Branford-based IsoPlexis has developed a technology called single-cell proteomics—the protein equivalent of genomics—that helps doctors better predict disease progression and develop more effective treatments. Featured in dozens of peer-reviewed scientific publications and with versatility demonstrated across a wide range of research areas, the company’s technology isolates single immune cells and analyzes the proteins they secrete. Once doctors understand how various illnesses act at the single-cell level, they can better predict how patients will respond to existing therapies or even create new treatments.